FAT1 and non-small cell lung carcinoma: A notable study by Feng et al. indicated a high mutation frequency of FAT1 in NSCLC (Feng et al., 2022), and they simultaneously discovered that patients harboring FAT1 mutations exhibited significantly increased infiltration of activated dendritic cells and extended progression-free survival from ICB treatment.